A novel variant in RUNX1 in a patient with refractory eosinophilic gastrointestinal disease and long-term clinical response to ketotifen
Abstract
Background: Eosinophilic gastrointestinal disease (EGID) is an umbrella term for a heterogeneous group of disorders affecting the GI tract. In contrast to the relatively common eosinophilic esophagitis (EoE), eosinophilic gastroenteritis (EGE) remains poorly understood in terms of both its pathophysiology and genetic etiology, while treatment options remain limited.
Aim: To expand the genotypic spectrum of EGE and describe our long-term experience of treatment with ketotifen.
Methods: Case report of a patient with EGE followed by our team for over 27 years.
Results: Our patient was diagnosed with EGE at the age of 4 years, accompanied by multiple other atopic manifestations and serum eosinophilia. He was later diagnosed with a heterozygous variant in RUNX1, a gene implicated in multi-lineage hematopoiesis, inhibition of Th2 polarization and T regulatory cell function. The patient has experienced long-term symptom improvement while treated with the mast cell stabilizing H1 antihistamine, ketotifen, with substantial symptomatic worsening after this agent was briefly stopped.
Conclusion: We expand the genotypic spectrum of EGID etiology to include mutations in RUNX1, and suggest ketotifen as a viable option for patients with treatment-refractory EGE.
Statement of novelty: This case reports on a possible novel genetic cause of EGID and describes long-term successful clinical management with ketotifen.
Formats available
You can view the full content in the following formats:
REFERENCES
Bolukbas F.F., Bolukbas C., Uzunkoy A., Baba F., Horoz M., and Ozturk E. 2004. Case report: a dramatic response to ketotifen in a case of eosinophilic gastroenteritis mimicking abdominal emergency. Dig. Dis. Sci. 49(11–12): 1782–1785.
Chang X., March M., Mentch F., Nguyen K., Glessner J., Qu H., Liu Y., Furuta G., Aceves S., Gonsalves N., Nadeau K., Cianferoni A., Spergel J., Sleiman P., and Hakonarson H. 2022. A genome-wide association meta-analysis identifies new eosinophilic esophagitis loci. J. Allergy Clin. Immunol. 149(3): 988–998.
Cohen M.M. Jr. 2009. Perspectives on RUNX genes: an update. Am. J. Med. Genet. A. 149A(12): 2629–2646.
Dellon E.S. and Spergel J.M. 2022. Biologics in eosinophilic gastrointestinal diseases. Ann. Allergy Asthma Immunol. 20: S1081-1206(22)00536-1.
Di Giacomo D., Quintini M., Pierini V., Pellanera F., La Starza R., Gorello P., Matteucci C., Crescenzi B., Fiumara P.F., Veltroni M., Borlenghi E., Albano F., Forghieri F., Maccaferri M., Bettelli F., Luppi M., Cuneo A., Rossi G., and Mecucci C. 2022. Genomic and clinical findings in myeloid neoplasms with PDGFRB rearrangement. Ann. Hematol. 101(2): 297–307.
Freeman H.J. 2009. Longstanding eosinophilic gastroenteritis of more than 20 years. Can. J. Gastroenterol. 23(9): 632–634.
Gonsalves N. 2019. Eosinophilic gastrointestinal disorders. Clin. Rev. Allergy Immunol. 57(2): 272–885.
Holmes A., Coviello J., and Velagaleti G. 2014. Acute multilineage (B/myeloid) leukemia with RUNX1 duplication/amplification and hypereosinophilia. Eur. J. Haematol. 93(5): 449–452.
Kanagal-Shamanna R., Loghavi S., DiNardo C.D., Medeiros L.J., Garcia-Manero G., Jabbour E., Routbort M.J., Luthra R., Bueso-Ramos C.E., and Khoury J.D. 2017. Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica. 102(10): 1661–1670.
Komine O., Hayashi K., Natsume W., Watanabe T., Seki Y., Seki N., Yagi R., Sukzuki W., Tamauchi H., Hozumi K., Habu S., Kubo M., and Satake M. 2003. The Runx1 transcription factor inhibits the differentiation of naive CD4+ T Cells into the Th2 Lineage by repressing GATA3 expression. J Exp Med. 198(1): 51–61.
Kottyan L.C., Trimarchi M.P., Lu X., Caldwell J.M., Maddox A., Parameswaran S., Lape M., D’Mello R.J., Bonfield M., Ballaban A., Mukkada V., Putnam P.E., Abonia P., Morgenstern N.B-B, Eapen A.A., Wen T., Weirauch M.T., and Rothenberg M.E. 2021. Replication and meta-analyses nominate numerous eosinophilic esophagitis risk genes. J. Allergy Clin. Immunol. 147(1):255–266.
Li Y., Yang W., Devidas M., Winter S.S., Kesserwan C., Yang W., Dunsmore K.P., Smith C., Qian M., Zhao X., Zhang R., Gastier-Foster J.M., Raetz E.A., Carroll W.L., Li C., Liu P.P., Rabin K.R., Sanda T., Mullighan C.G., Nichols K.E., Evans W.E., Pui C.H., Hunger S.P., Teachey D.T., Relling M.V., Loh M.L., and Yang J.J. 2021. Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia. J. Clin. Invest. 131(17): e147898.
Melamed I. and Roifman C.M. 1991. Benefit of ketotifen in patients with eosinophilic gastroenteritis. Am. J. Med. 90(3): 310–314.
Ono M., Yaguchi H., Ohkura N., Kitabayashi I., Nagamura Y., Nomura T., Miyachi Y., Tsukada T., and Sakaguchi S. 2007. Foxp3 controls regulatory T-cell function by interacting with AML1/Runx1. Nature. 446(7136): 685–689.
Rossi C.M., Lenti M.V., Merli S., Licari A., Votto M., Marseglia G.L., and Sabatino A.D. 2022. Primary eosinophilic gastrointestinal disorders and allergy: clinical and therapeutic implications. Clin Transl Allergy [Internet]. [cited 2022 Jul 7]; 12(5).
Ryu S., Lee K.H., Tizaoui K., Terrazzino S., Cargnin S., Effenberger M., Shin J.I., and Kronbichler A. 2020. Pathogenesis of eosinophilic esophagitis: a comprehensive review of the genetic and molecular aspects. Int J Mol Sci. 21(19):7253.
Schmit J.M., Turner D.J., Hromas R.A., Wingard J.R., Brown R.A., Li Y., Li M.M., Slayton W.B., and Cogle C.R. 2015. Two novel RUNX1 mutations in a patient with congenital thrombocytopenia that evolved into a high grade myelodysplastic syndrome. Leuk Res Rep. 4(1): 24–27.
Schwaab J., Cabral do O Hartmann N., Naumann N., Jawhar M., Weiß C., Metzgeroth G., Schmid A., Lübke J., Reiter L., Fabarius A., Cross N.C.P., Sotlar K., Valent P., Kluin-Nelemans H.C., Hofmann W-K., Horny H-P., Panse J., and Reiter A. 2020. Importance of adequate diagnostic workup for correct diagnosis of advanced systemic mastocytosis. J. Allergy Clin. Immunol. Pract. 8(9): 3121–3127.e1.
Simon L., Spinella J.F., Yao C.Y., Lavallée V.P., Boivin I., Boucher G., Audemard E., Bordeleau M-E., Lemieux S., Hébert J., and Sauvageau G. 2020. High frequency of germline RUNX1 mutations in patients with RUNX1-mutated AML. Blood. 135(21): 1882–1886.
Tang K.H., Li S., Khodadadi-Jamayran A., Jen J., Han H., Guidry K., Chen T., Hao Y., Fedele C., Zebala J.A., Maeda D.Y., Christensen J.G., Olson P., Athanas A., Loomis C.A., Tsirigos A., Wong K-K., and Neel B.G. 2022. Combined inhibition of SHP2 and CXCR1/2 promotes antitumor T-cell response in NSCLC. Cancer Discov. 12(1): 47–61.
Information & Authors
Information
Published In
LymphoSign Journal
Volume 9 • Number 3 • September 2022
Pages: 72 - 76
History
Received: 15 August 2022
Accepted: 28 August 2022
Accepted manuscript online: 30 August 2022
Copyright
© 2022.
Authors
Metrics & Citations
Metrics
Other Metrics
Citations
Cite As
OriScott, JennyGarkaby, LauraAbrego Fuentes, Chaim M.Roifman, and JessicaWillett Pachul. 2022. A novel variant in RUNX1 in a patient with refractory eosinophilic gastrointestinal disease and long-term clinical response to ketotifen. LymphoSign Journal.
9(3): 72-76. https://doi.org/10.14785/lymphosign-2022-0010
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
Cited by
1. Corrigendum: A novel variant in RUNX1 in a patient with refractory eosinophilic gastrointestinal disease and long-term clinical response to ketotifen
View Options
Get Access
Login options
Check if you access through your login credentials or your institution to get full access on this article.
